Nurix Therapeutics Inc (NASDAQ: NRIX) kicked off on Monday, up 8.03% from the previous trading day, before settling in for the closing price of $11.09. Over the past 52 weeks, NRIX has traded in a range of $8.18-$29.56.
Annual sales at Healthcare sector company slipped by -38.86% over the past five years. While this was happening, its average annual earnings per share was recorded -10.26%. With a float of $75.35 million, this company’s outstanding shares have now reached $76.87 million.
Nurix Therapeutics Inc (NRIX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.99%, while institutional ownership is 115.28%. The most recent insider transaction that took place on Aug 01 ’25, was worth 59,598. In this transaction Chief Financial Officer of this company sold 5,402 shares at a rate of $11.03, taking the stock ownership to the 35,512 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Officer proposed sale 5,402 for $11.26, making the entire transaction worth $60,827.
Nurix Therapeutics Inc (NRIX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 11/30/2024, the organization reported -0.75 earnings per share (EPS), lower than consensus estimate (set at -0.67) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -6.99% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Take a look at Nurix Therapeutics Inc’s (NRIX) current performance indicators. Last quarter, stock had a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.70 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ: NRIX) saw its 5-day average volume 3.15 million, a positive change from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 75.08%.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 59.46%, which indicates a significant decrease from 97.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.80 in the past 14 days, which was higher than the 0.62 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.54, while its 200-day Moving Average is $12.17. Nevertheless, the first resistance level for the watch stands at $12.30 in the near term. At $12.61, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.17. If the price goes on to break the first support level at $11.43, it is likely to go to the next support level at $10.87. The third support level lies at $10.56 if the price breaches the second support level.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
The company with the Market Capitalisation of 1.21 billion has total of 76,883K Shares Outstanding. Its annual sales at the moment are 54,550 K in contrast with the sum of -193,570 K annual income. Company’s last quarter sales were recorded 7,890 K and last quarter income was -86,420 K.
